loading

Cullinan Therapeutics Inc Aktie (CGEM) Neueste Nachrichten

pulisher
Jun 05, 2025

Cullinan Therapeutics Licenses Rights to Velinotamig from Genrix Bio - Contract Pharma

Jun 05, 2025
pulisher
Jun 05, 2025

Cullinan Therapeutics Stock Slides After-Hours Despite $692M Autoimmune Drug Pact With Genrix - MENAFN.com

Jun 05, 2025
pulisher
Jun 05, 2025

Cullinan Therapeutics Stock Slides After-Hours Despite $692M Autoimmune Drug Pact With Genrix By Stocktwits - Investing.com India

Jun 05, 2025
pulisher
Jun 04, 2025

Transcript : Cullinan Therapeutics, Inc.Special Call - marketscreener.com

Jun 04, 2025
pulisher
Jun 04, 2025

Cullinan expands autoimmune focus with new T cell engager license By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 04, 2025

Cullinan (CGEM) Secures Global Rights for Velinotamig from Genri - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Cullinan Therapeutics (CGEM) Secures Exclusive License for Velin - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Cullinan Management Enters Global License Agreement with Genrix - TipRanks

Jun 04, 2025
pulisher
Jun 04, 2025

Cullinan Therapeutics in pact with Genrix Bio for velinotamig (CGEM:NASDAQ) - Seeking Alpha

Jun 04, 2025
pulisher
Jun 04, 2025

Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases | CGEM Stock News - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Cullinan Therapeutics Licenses Rights to Velinotamig - marketscreener.com

Jun 04, 2025
pulisher
Jun 04, 2025

Cullinan Therapeutics Licenses Rights to Velinotamig, a - GlobeNewswire

Jun 04, 2025
pulisher
Jun 04, 2025

Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific ... - Eagle-Tribune

Jun 04, 2025
pulisher
Jun 04, 2025

Bank of America Corp DE Cuts Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Sold by Nuveen Asset Management LLC - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Sees Significant Decline in Short Interest - Defense World

Jun 02, 2025
pulisher
Jun 01, 2025

Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILI - GuruFocus

Jun 01, 2025
pulisher
Jun 01, 2025

Cullinan Therapeutics IncTaiho Oncology And Cullinan Therapeutics Publish Positive Rezilient1 Trial Results - marketscreener.com

Jun 01, 2025
pulisher
Jun 01, 2025

Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology - PR Newswire

Jun 01, 2025
pulisher
Jun 01, 2025

ProShare Advisors LLC Acquires 4,124 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

Jun 01, 2025
pulisher
May 29, 2025

Cullinan Therapeutics to Host Analyst and Investor Event at - GlobeNewswire

May 29, 2025
pulisher
May 29, 2025

Cullinan Therapeutics to Host Analyst and Investor Event at 2025 - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference | CGEM Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference - The Globe and Mail

May 29, 2025
pulisher
May 26, 2025

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Sold by D. E. Shaw & Co. Inc. - Defense World

May 26, 2025
pulisher
May 24, 2025

Ameriprise Financial Inc. Raises Stake in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

May 24, 2025
pulisher
May 22, 2025

Cullinan Therapeutics (CGEM) Reveals Promising Phase 2b Results - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology Announce Positive Results from REZILIENT1 Trial of Zipalertinib in Advanced Lung Cancer Patients - Nasdaq

May 22, 2025
pulisher
May 22, 2025

Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025 - GlobeNewswire

May 22, 2025
pulisher
May 21, 2025

Northern Trust Corp Raises Stock Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

May 21, 2025
pulisher
May 20, 2025

115,000 Shares in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Acquired by BNP Paribas Financial Markets - Defense World

May 20, 2025
pulisher
May 15, 2025

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Stake Boosted by Price T Rowe Associates Inc. MD - Defense World

May 15, 2025
pulisher
May 14, 2025

Cullinan Therapeutics (CGEM) Projected to Announce Quarterly Earnings on Wednesday - Defense World

May 14, 2025
pulisher
May 13, 2025

Cullinan Therapeutics (CGEM): UBS Lowers Price Target but Mainta - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Cullinan Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 13, 2025
pulisher
May 13, 2025

Cullinan Therapeutics (NASDAQ:CGEM) Price Target Lowered to $24.00 at UBS Group - Defense World

May 13, 2025
pulisher
May 12, 2025

UBS Adjusts Price Target on Cullinan Therapeutics to $24 From $30, Maintains Buy Rating - marketscreener.com

May 12, 2025
pulisher
May 12, 2025

Cullinan Therapeutics (CGEM) Price Target Revised by UBS Analyst - GuruFocus

May 12, 2025
pulisher
May 10, 2025

Cullinan Therapeutics Inc Reports Q1 2025 EPS Below Estimates wi - GuruFocus

May 10, 2025
pulisher
May 10, 2025

Cullinan Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 10, 2025
pulisher
May 09, 2025

Cullinan Therapeutics: Q1 Earnings Snapshot - New Haven Register

May 09, 2025
pulisher
May 09, 2025

Dimensional Fund Advisors LP Acquires 295,467 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

May 09, 2025
pulisher
May 08, 2025

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results - GlobeNewswire

May 08, 2025
pulisher
May 08, 2025

Cullinan Oncology (CGEM) Projects Financial Runway through 2028 | CGEM Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Cullinan Therapeutics (CGEM) Advances Autoimmune and Oncology Programs | CGEM Stock News - GuruFocus

May 08, 2025
$1.15
price up icon 1.30%
$584.68
price up icon 0.75%
$308.75
price up icon 1.19%
$37.33
price up icon 2.30%
$4.68
price down icon 3.35%
$492.00
price up icon 1.78%
Kapitalisierung:     |  Volumen (24h):